Avita Medical, Inc. · NASDAQ:RCEL
Avita Medical — Shareholder Meeting (November 2010)
35 slides from Avita Medical's shareholder meeting presentation, Nov 30, 2010
Slide 1: Annual General Meeting, Perth, 30 November 2010
William Dolphin, Ph.D. Chief Executive Officer Galatéa de las esferas Salvador Dalí, 1952 Annual General Meeting Perth, Australia 30 November 2010
Slide 2: Forward-looking statements
2 This presentation may include forward‐looking statements. You can identify these statements by the fact that they use words such as “anticipate”, “estimate”, “expect”, “project”, “potential”, “intend”, “plan”, “believe”, “target”, “may”, “assume” or similar expressions. These forward looking state
Slide 3: Agenda
3 Review of original Strategic Plan Performance to date Initial product: ReCell Spray‐On Skin − Product Description − Market Opportunity
Slide 4: Our Mission
4 Our Mission: Create a leading global healthcare company in the field of regenerative medicine and tissue engineering, providing innovative, highly differentiated and cost‐effective solutions that address the needs of patients, clinicians and healthcare systems while delivering above average retu
Slide 5: Goal: Regrow, replace, restore function of tissues
5 Goal: Regrow, replace, restore function of tissues, organs or limbs damaged, lost or non‐functional (e.g., trauma, disease, senescence). Fundamental change to practice of medicine All tissues and organs – in theory – have capability to regenerate Initial Product : ReCell® Spray‐On Skin
Slide 6: Three-year strategic plan by year
6 Year 1 (30 June 2009) Year 2 (30 June 2010) Year 3 (30 June 2011) Assess: Build organisation: Implement Sales & ¾ Organisational structure ¾ Put teams in place: Marketing Plan ¾ Personnel management, ops, sales ¾ Mixed model: direct & ¾ Market – ReCell Go/No Go ¾ Revamp Operations & distribu
Slide 7: Strategic priorities
7 Increase sales revenues in high value markets Implement “continuous improvement” models to operations Tighten management of working capital Obtain regulatory approvals in key markets Strengthen product portfolio and expand intellectual property
Slide 8: Revenue, $M
8 •Increase sales revenues in high value markets • Focused efforts on key markets, establishing KOLs and centres of excellence Revenue, $M • 2‐year growth of 99%: • 2008: $1.9M • 2009: $3.2M • 2010: $3.9M
Slide 9: Gross Margin
9 • Implement “continuous improvement” models to operations • Gross margins improved with continued gains in manufacturing efficiencies. • 2‐year improvement of 97% Gross Margin • 2008: 38% • 2009: 54% • 2010: 75%
Slide 10: Operating Loss, $M
10 •Tighten management of working capital • Ongoing efforts at cost containment and improved efficiencies continue to positively impact cash flow. Operating Loss, $M • 2‐year reduction of operating losses of of 78%: • 2008: $12.5M • 2009: $5.1M • 2010: $2.7M* • Corporate restructure: Stock repurchas
Slide 11: Obtain regulatory approvals in key markets
11 Obtain regulatory approvals in key markets − Regulatory clearance in Europe (CE Marked), Australia (TGA), China (SFDA) − US FDA trials underway ▪ US$2M grant from US DoD (AFIRM) – Burns ▪ US$2M contract from US DoD (OTT) – Scar
Slide 12: US DoD (AFIRM) burns trial
12 $1.95 M funding from US DoD (AFIRM) Primary Objective: Demonstration of safety and efficacy of ReCell in the treatment of acute burns in comparison to current standard‐of‐care, split‐thickness skin graft (STSG) − US FDA product approval Endpoints: − Time to healing − Morbidity (infections,
Slide 13: US DoD (OTT) scar trial
13 $1.9 M contract with US DoD (OTT) Primary Objective: Demonstration of safety and efficacy of ReCell in the treatment of scars resulting from meshed, split‐thickness skin graft (STSG) − US FDA product approval Endpoints (proposed): − Elimination of Scarring (matching to surrounding, undamage
Slide 14: Strengthen product portfolio and expand intellectual property
14 Strengthen product portfolio and expand intellectual property − 7 patents granted (US, PCT, Australia, Japan) − 6 applications pending
Slide 15: Market Opportunities
Market Opportunities 2013 Market Opportunities 6 Wound Management & Regenerative Medicine 5 Infusion / Delivery Degree of Innovation 4 Ortho / Spinal Implants Orthobiologics 3 Steroid-Eluting Electrode 2 Antibiotic Bone Cement 1 Drug-Eluting Stents *Bubbles denote market size 0 0.0% 5.0% 10.0% 15.0%
Slide 16: Geographic expansion
16 Australia/New Zealand Europe − Expand beyond current UK, France, Germany Asia − Taiwan − China (forming JV) − India/SE Asia Middle East Russia United States
Slide 17: Avita's regenerative technology
17 Avita’s regenerative technology: Harnesses body’s intrinsic ability to heal itself and packages it into an easy‐to‐use bedside kit for the clinician. Patients: Provides improved outcomes. Surgeon/Clinician: Easy, fast and effective with reduced morbidity. Healthcare Provider: Reduced cost
Slide 18: Applications
18 Applications: Burns, scalds and donor sites associated with grafts Scar revisions to improve colour, texture & function Pigmentation disorders such as Vitiligo Epidermal defects such as naevi, acne, discolouration Prophylactic aesthetic rejuvenation procedures
Slide 19: Patient results over time
19 Day 1 Prep and debridement 3 Weeks post ReCell 10 Months post ReCell
Slide 20: Neck pre-treatment and 12 months post ReCell
20 Neck pre‐treatment 12‐months post ReCell®
Slide 21: Pre-ReCell and 10 months post-ReCell
21 Pre‐ ReCell 10 month post‐ ReCell
Slide 22: Pre-ReCell and 12 months post-ReCell
22 Pre‐ ReCell 12 month post‐ ReCell
Slide 23: Pre-ReCell and 12 months post-ReCell
23 Pre‐ ReCell 12 month post‐ ReCell
Slide 24: Skin Structure and progenitor cells
Skin Structure Openings of Sweat Glands Horny Layer | Granular Layer EPIDERMIS EST ease ee etter r o<— Prickle-Cell Layer . a Progenitor SKIN _\+———_ Basal Layer cells DERMIS - Subaceous Gland one ene eee eee = 4 ‘ — - Blood Vessels Hair Follicle ———= : Le y Nerves Subcutaneous Fatty Tissue avita
Slide 25: ReCell procedure steps
25 1. Thin, split‐thickness biopsy (200 x 200 x 0.2 mm) of similar skin (‘site matched’) 2. Biopsy incubated in enzyme ‘cocktail’ approx 20 min 1. 2. 3. Biopsy removed from incubator, mechanically agitated to separate cells 4. Cells rinsed in ‘buffer cocktail’ 3. 4. 5. Suspension filtered 6. Suspens
Slide 26: Cells collected from dermal-epidermal junction
26 Cells collected from dermal‐epidermal junction include: − Keratinocytes − Melanocytes − Fibroblasts − Langerhans Cells − Un‐differentiated Basal cells These cells: − Are not yet terminally differentiated − Pre‐confluent − Are highly proliferative − Cultured in‐situ − Migrate evenly across the
Slide 27: ReCell suspension sprayed onto wound surface
27 Result: ‘normal’, healthy, new skin with full complement of constituent ReCell suspension cells types, including melanocytes, sprayed onto keratinocytes, fibroblasts and basal wound surface cells in proper proportion Disaggregated Cell signalling cells migrate encourages and directs over wound ar
Slide 28: Wound Care, Plastics, Aesthetics applications
28 Wound Care Plastics Aesthetics ‐ Burns ‐ Scar remodelling ‐ Cosmetic relief ‐ ReCell Alone ‐ Pre‐existing ‐ Acne scars ‐ Combination with ‐ Burn, graft scars ‐ Hyper or hypo‐ other treatments ‐ Surgical scars pigmentation (e.g., mesh grafts, ‐ Biopsy ‐ Liver spots dermal substitutes) ‐ Mohs surge
Slide 29: ReCell Markets
ReCell® Markets Burns 450,000 Burns requiring surgical intervention (2) Plastic / 580,000 (US) Treatments sought from plastic Dermatology / surgeons for scar remodeling. (3) Reconstructive Vitiligo 200,000 ? Reported cases seeking treatment (prevalence: 2% of population ~ 12 million) (4) Aesthetics
Slide 30: Competition
Competition Skin graft Cultured epithelia (auto or allo) Artificial skin Dermal matrixes ReCell Spray-On Skin * Standard of care + Specific graft procedure inexpensive + Rapid procedure + Large coverage * Small donor site + Low infection + Large coverage * No donor site + Low infection / reject + Re
Slide 31: Competition
Competition Skin graft: Cultured epithelia (autologous, allogeneic or xenogeneic) Dermal matrixes Spray-on (ReCell) 3M Health Care Baxter Carrington Laboratories, Inc. ConvaTec, Ltd. Covidien, Ltd Derma Sciences GlaxoSmithKline Plc Healthpoint, Ltd. Advanced BioHealing Ethicon Fidia Farmaceutici s.p
Slide 32: Management team
32 William F. Dolphin, Ph.D., CEO; 28 years international executive experience; significant M&A experience. Andrew Quick, VP Research & Technology; 20 years medical device experience; expertise in design, development and clinical research. Lorraine Glover, General Manager, Asia Pacific; 20 years in
Slide 33: Major progress on all fronts
33 Major progress on all operational, strategic and corporate fronts: Increased sales revenues Improved margins Decreased cash burn Support of key influential surgeons and Centres of Excellence Support of US Dept of Defense Experienced management team in place Unique, ‘paradigm‐shiftin
Slide 34: 34
34
Slide 35: Thank you
Thank you avita